ArticleJournal of ethnopharmacology2021
Evaluating the Traditional Chinese Medicine (TCM) Officially Recommended in China for COVID-19 Using Ontology-Based Side-Effect Prediction Framework (OSPF) and Deep Learning.
Article in Journal of ethnopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Pooled it
- Artificial intelligence and computational methods in the Asia-Pacific pharmacovigilance landscape: a systematic review.International journal of public health · 2026Pooled it
- Advancing the modernization of traditional Chinese medicine through artificial intelligence and multimodal data integration.Chinese medicine · 2026Review
- The integration of machine learning into traditional Chinese medicine.Journal of pharmaceutical analysis · 2025Review
- A Machine Learning Approach to Differentiate Cold and Hot Syndrome in Viral Pneumonia Integrating Traditional Chinese Medicine and Modern Medicine: Machine Learning Model Development and Validation.JMIR medical informatics · 2025Article
- TCMRD - KG: innovative design and development of rheumatology knowledge graph in ancient Chinese literature assisted by large language models.Frontiers in pharmacology · 2025Article
- TongueNet: a multi-modal fusion and multi-label classification model for traditional Chinese Medicine tongue diagnosis.Frontiers in physiology · 2025Article
- Suboptimal capability of individual machine learning algorithms in modeling small-scale imbalanced clinical data of local hospital.PloS one · 2024Article
- Machine Learning Research Trends in Traditional Chinese Medicine: A Bibliometric Review.International journal of general medicine · 2024Review
- The Role of Traditional Chinese Medicine and Chinese Pharmacopoeia in the Evaluation and Treatment of COVID-19.Current pharmaceutical design · 2024Review
- Application of Data Fusion in Traditional Chinese Medicine: A Review.Sensors (Basel, Switzerland) · 2023Review
- Artificial Intelligence, Machine Learning, and Big Data for Ebola Virus Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers.Frontiers in pharmacology · 2023Article
- Evolution from Medical Imaging to Visualized Medicine.Advances in experimental medicine and biology · 2023Article
- Machine Learning Applications in Drug Repurposing.Interdisciplinary sciences, computational life sciences · 2022Review
- Covid-19 and Artificial Intelligence: Genome sequencing, drug development and vaccine discovery.Journal of infection and public health · 2022Review
- The Use of Artificial Intelligence in Complementary and Alternative Medicine: A Systematic Scoping Review.Frontiers in pharmacology · 2022Article
- A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019.Journal of personalized medicine · 2021Review
- An Improved Deep Learning Model: S-TextBLCNN for Traditional Chinese Medicine Formula Classification.Frontiers in genetics · 2021Article
- Chinese Medicine Formula Huashibaidu Granule Early Treatment for Mild COVID-19 Patients: An Unblinded, Cluster-Randomized Clinical Trial.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ethnopharmacological relevanceThe novel coronavirus disease (COVID-19) outbreak in Wuhan has imposed a huge influence in terms of public health and economy on society. However, no effective drugs or vaccines have been developed so far. Traditional Chinese Medicine (TCM) has been considered as a promising supplementary treatment of this disease due to its clinically proven performance in many severe diseases, like severe acute respiratory syndrome (SARS). Meanwhile, many reports suggest that the side-effects (SE) of TCM prescriptions cannot be ignored in treating COVID-19 as it often leads to dramatic degradation of the patients' physical condition. Systematic evaluation of TCM regarding its latent SE becomes a burning issue.
aimIn this study, we used an ontology-based side-effect prediction framework (OSPF) developed from our previous work and Artificial Neural Network (ANN)-based deep learning, to evaluate the TCM prescriptions officially recommended by China for the treatment of COVID-19. MATERIALS AND
methodsThe OSPF developed from our previous work was implemented in this study, where an ontology-based model separated all ingredients in a TCM prescription into two categories: hot and cold. A database was created by converting each TCM prescription into a vector which contained ingredient dosages, corresponding hot/cold attribution and safe/unsafe labels. This allowed for training of the ANN model. A safety indicator (SI), as a complement to SE possibility, was then assigned to each TCM prescription. According to the proposed SI, from high to low, the recommended prescription list could be optimized. Furthermore, in interest of expanding the potential treatment options, SIs of other well-known TCM prescriptions, which are not included in the recommended list but are used traditionally to cure flu-like diseases, are also evaluated via this method.
resultsBased on SI, QFPD-T, HSBD-F, PMSP, GCT-CJ, SF-ZSY, and HSYF-F were the safest treatments in the recommended list, with SI scores over 0.8. PESP, QYLX-F, JHQG-KL, SFJD-JN, SHL-KFY, PESP1, XBJ-ZSY, HSZF-F, PSSP2, FFTS-W, and NHSQ-W were the prescriptions most likely to be unsafe, with SI scores below 0.1. In the additional lists of other TCM prescriptions, the indicators of XC-T, SQRS-S, CC-J, and XFBD-F were all above 0.8, while QF-Y, XZXS-S, BJ-S, KBD-CJ, and QWJD-T's indicators were all below 0.1.
conclusionsIn total, there were 10 TCM prescriptions with indicators over 0.8, suggesting that they could be considered in treating COVID-19, if suitable. We believe this work could provide reasonable suggestions for choosing proper TCM prescriptions as a supplementary treatment for COVID-19. Furthermore, this work introduces a novel and informative method which could help create recommendation list of TCM prescriptions for the treatment of other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.